Project Grant R21AA031776
Award Date
9/20/24
Completion Date
8/31/26
Dollars Obligated
$224K
Federal Agency
National Institute on Alcohol Abuse and Alcoholism
Federal Grant Program
93.273
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...
This federal Project Grant award of $581,869 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the CFDA 93.273 Alcohol Research Programs, will fund a human neuroscience study to investigate the role of glucocorticoid receptor (GR) antagonism in alcohol use disorder (AUD). The study will evaluate the effects of a selective GR antagonist, PT150, on behavioral, neuroendocrinological, and physiological responses to stress and alcohol in 34 participants. The research aims...
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) funding opportunity, supports the investigational new drug development of noribogaine for the treatment of alcohol use disorder (AUD). The awardee, Demerx, Inc., a Miami-based clinical stage drug development company, will use the $914,324 in funding awarded on August 1, 2025 to conduct IND-enabling nonclinical studies, including subchronic repeat...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $537,587 Project Grant under the Alcohol Research Programs (CFDA 93.273) to The University of Texas Southwestern Medical Center to conduct research on the metabolic consequences of liver inflammation on alcohol consumption and alcohol-associated liver disease (ALD). The key objectives are to identify the mechanisms by which the transcription factor IRF3 suppresses the expression and secretion of the metabolic regulator...
This $366,406 Project Grant was awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to Yale University. The grant will be used to develop two novel human laboratory models to screen potential medications for Alcohol Use Disorder (AUD). The first model will assess a medication's ability to increase abstinence and reduce heavy drinking, which align with key FDA endpoints for AUD medication approval. The second model will...
This federal Project Grant award of $1,135,243 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will support research to investigate changes in neural mechanisms associated with cognitive reappraisal and alcohol cue reactivity during early abstinence from alcohol use disorder (AUD) treatment. The research, conducted by the University of Colorado-Denver and involving sub-awards to Emory University and the University of Denver,...
This $856,625 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), supports an exploratory randomized controlled trial (RCT) of the effects of oral semaglutide on alcohol craving and consumption. The University of Colorado-Denver, as the prime awardee, will conduct this 2-year study to assess the safety, tolerability, and efficacy of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, compared to placebo...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $1,547,718 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) from September 1, 2024 to May 31, 2029. The project will investigate the role of KDM5 demethylases in regulating cell-cell communication in the development and resolution of alcohol-associated liver disease. Specifically, the research aims to determine how KDM5B and KDM5C...
This $244,393 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), aims to evaluate the safety, tolerability, and efficacy of intranasal insulin administration as a potential treatment for alcohol use disorder (AUD). The key objectives of this Phase I/IIa clinical study are to: 1) assess the safety and tolerability of intranasal insulin in 40 non-treatment-seeking individuals with AUD; 2) evaluate the difference...
The federal Project Grant award R00AA030665 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program. The $249,001 award, effective May 1, 2025, supports a study entitled "Study Aimed at Increasing Alcohol Abstinence (DEDICATE)" to be conducted by the University of Illinois. The key objectives of this project are to (1) test the efficacy of combining contingency management (CM) with...